Amy H. Huang, PGY-3 Internal Medicine Resident at The University of Connecticut, shared a post on X about a recent article she and her colleagues co-authored, adding:
“Publication Alert
Our Conquer Cancer Merit Award-winning meta-analysis on EGFR inhibitor rechallenge for metastatic colorectal cancer has been published in JCO Oncology Practice (first and corresponding author)!
We showed that EGFR inhibitor rechallenge was associated with a significantly longer PFS, with the greatest benefit seen in patients with RAS/RAF wild-type disease confirmed by ctDNA testing. The response rates exceeded FDA-approved historical controls in the third-line setting, with manageable toxicity even in later-line use.
Grateful to my mentors Ronan Hsieh, Jyoti Malhotra, E. Gabriela Chiorean for their guidance and unwavering support!”
Title: Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Authors: Amy H. Huang, Gin Yi Lee, Chuan Angel Lu, Ibrahim Halil Sahin, Gentry T. King, Rachael A. Safyan, Stacey A. Cohen, David B. Zhen, Veena Shankaran, William P. Harris, Andrew L. Coveler, Jyoti Malhotra, Victoria E. Forbes, Philip J. Gold, E. Gabriela Chiorean, Ronan W. Hsieh
Read the Full Article on JCO Oncology Practice
More posts featuring Amy H. Huang.